US study backs Diatide's lung cancer imaging agent
This article was originally published in Clinica
Diatide's nuclear medicine imaging agent NeoTect is just as effective at detecting a prevalent form of lung cancer as the more expensive positron emission tomography (PET) imaging technique, a study has suggested.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.